^
    1year
    Novel phloretin-based combinations targeting glucose metabolism in hepatocellular carcinoma through GLUT2/PEPCK axis of action: in silico molecular modelling and in vivo studies. (PubMed, Med Oncol)
    We investigated novel anti-HCC treatments through either the simultaneous inhibition of glycolysis and gluconeogenesis by "phloretin" and "sodium meta-arsenite", respectively (Combination 1); or the concurrent inhibition of glycolysis and induction of gluconeogenesis by phloretin and dexamethasone, respectively, (combination 2). Biochemically, both combinations caused a significant reduction in ATP levels, ALT, and AST activity compared to the other groups. In conclusion, we propose two novel phloretin-based combinations that can be used in treating HCC through the regulation of glucose metabolism and ATP production.
    Preclinical • Journal
    |
    CCND1 (Cyclin D1) • CASP3 (Caspase 3) • BECN1 (Beclin 1)
    |
    CCND1 expression • RXRA overexpression
    |
    Kominox (sodium metaarsenite)
    4years
    Anti-Tumor Effects of Sodium Meta-Arsenite in Glioblastoma Cells with Higher Akt Activities. (PubMed, Int J Mol Sci)
    Finally, we illustrated in vivo anti-tumor effects of KML001 using an intracranial xenograft mouse model. These results suggest that KML001 could be an effective chemotherapeutic drug for the treatment of glioblastoma cancer patients with higher Akt activity and PTEN loss.
    Journal
    |
    PTEN (Phosphatase and tensin homolog)
    |
    PTEN expression • PTEN loss
    |
    Kominox (sodium metaarsenite)